A strategy to improve efficiency and reduce side effects of current PPAR agonists is to develop dual- or pan-PPAR agonists targeting multiple PPARs to achieve a balanced efficacy-tolerability profile for the treatment of T2D patients19. This evidence concerns the gene PPARA and type 2 diabetes mellitus.